약물학연구실
부산대학교 본교(제1캠퍼스) 약학대학
황성환 교수
Nonalcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease
Liver Injury
발행물
전체 논문
41
11
Distinct histopathological phenotypes of severe alcoholic hepatitis suggest different mechanisms driving liver injury and failure.
Ma J, Guillot A, Yang Z, Mackowiak B, Hwang S, Park O, Peiffer BJ, Ahmadi AR, Melo L, Kusumanchi P, Huda N, Saxena R, He Y, Guan Y, Feng D, Sancho-Bru P, Zang M, Cameron AM, Bataller R, Tacke F, Sun Z, Liangpunsakul S, Gao B
J Clin Invest, 2022
12
Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis
Chung KW, Cho YE, Kim SJ, Hwang S
Arch Pharm Res, 2022
13
Inhibitory effects of Rocaglamide-A on PPARg-driven adipogenesis through regulation of mitotic clonal expansion involving the JAK2/STAT3 pathway.
Ha YS, Kim TK, Park KS, Hwang S, Kim J, Kim SJ
Biochim Biophys Acta Mol Cell Biol Lipids, 2022
14
Crosstalk between oxidative stress and inflammatory liver injury in the pathogenesis of alcoholic liver disease.
Yang YM, Cho YE, Hwang S
Int J Mol Sci, 2022
15
E-selectin-dependent inflammation and lipolysis in adipose tissue exacerbate steatosis-to-steatohepatitis progression via S100A8/9.
Rodrigues RM, He Y, Hwang S, Bertola A, Mackowiak B, Ait-Ahmed Y, Seo W, Ma J, Wang X, Park SH, Guan Y, Fu Y, Vanhaecke T, Feng D, Gao B
Clin Mol Gastroenterol Hepatol, 2022
16
Type 1 polyisoprenoid diphosphate phosphatase modulates geranylgeranyl-mediated control of HMG CoA reductase and UBIAD1.
Elsabrouty R, Jo Y, Hwang S, Jun DJ, DeBose-Boyd RA
eLife, 2021
17
Targeting fatty acid metabolism for fibrotic disorders.
Hwang S, Chung KW
Arch Pharm Res, 2021
18
f HMG CoA reductase and UBIAD1.
eLife, 2021
19
Role of neutrophils in the pathogenesis of nonalcoholic steatohepatitis.
Hwang S, Yun H, Moon S, Cho YE, Gao B
Front Endocrinol, 2021
20
Exosomal microRNAs as diagnostic and therapeutic biomarkers in non-malignant liver diseases.
Hwang S, Yang YM
Arch Pharm Res, 2021